Ranbaxy's manufacturing mess results in $606M loss

The manufacturing problems that brought about groundbreaking Department of Justice oversight of Ranbaxy Laboratories ($RBXY) has led to a $500 million charge and a $606 million loss for the fourth quarter. That loss represents the biggest quarterly loss in four years for India's largest generic drugmaker. In addition to significant lapses in its manufacturing practices, the FDA and DOJ found that Ranbaxy had falsified documentation. The consent decree forced the company to upgrade facilities, lose exclusivity on some drugs for a period and even set up an employee whistleblower program. Story | More 
 

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.